Literature DB >> 24402138

Does a history of suicide attempt predict higher antipsychotic dosage in schizophrenia?

Nuwan C Hettige1, James L Kennedy, Vincenzo De Luca.   

Abstract

RATIONALE: Antipsychotic dosage is generally adjusted by physicians depending on the stability of the patient and the response to that particular drug. Our hypothesis is that patients with previous suicide attempt are prescribed higher doses of antipsychotics.
OBJECTIVE: We examined the dosage and patterns of antipsychotic use in regard to past suicidal behaviour.
METHODS: For this study, 304 subjects with schizophrenia spectrum disorders between the ages of 18 and 75 were recruited. A cross-sectional assessment was used for this study, in which data were collected from each patient through an interview and self-report questionnaires. The percentages of the Compendium of Pharmaceuticals and Specialties (CPS) maximum recommended daily dose were applied to standardize antipsychotic dosages across different treatments. We compared the standardized dosage of antipsychotics in schizophrenics with previous suicide attempts and those who have never attempted suicide.
RESULTS: Applying the ANCOVA, our preliminary results show no significant difference (P = 0.467) in antipsychotic dosage in the attempters and non-attempters. The prescribed clozapine dosage fails to show a significant relationship with suicidal history (P >0.05).
CONCLUSIONS: In summary, our analysis does not show antipsychotic dosage adjustment based on past suicide attempt, after controlling for the current suicidal ideation and hopelessness.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24402138     DOI: 10.1007/s00213-013-3419-8

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  36 in total

1.  Depression in schizophrenia: recognition and management in the USA.

Authors:  S G Siris; D Addington; J M Azorin; I R Falloon; J Gerlach; S R Hirsch
Journal:  Schizophr Res       Date:  2001-03-01       Impact factor: 4.939

Review 2.  Schizophrenia and suicide: systematic review of risk factors.

Authors:  Keith Hawton; Lesley Sutton; Camilla Haw; Julia Sinclair; Jonathan J Deeks
Journal:  Br J Psychiatry       Date:  2005-07       Impact factor: 9.319

Review 3.  Update on typical and atypical antipsychotic drugs.

Authors:  Herbert Y Meltzer
Journal:  Annu Rev Med       Date:  2012-09-27       Impact factor: 13.739

Review 4.  Schizophrenia and suicide.

Authors:  Y Ps Balhara; R Verma
Journal:  East Asian Arch Psychiatry       Date:  2012-09

5.  Predictors of antipsychotic dose changes in the CATIE schizophrenia trial.

Authors:  Eric Hermes; Robert Rosenheck
Journal:  Psychiatry Res       Date:  2012-04-20       Impact factor: 3.222

6.  The lifetime risk of suicide in schizophrenia: a reexamination.

Authors:  Brian A Palmer; V Shane Pankratz; John Michael Bostwick
Journal:  Arch Gen Psychiatry       Date:  2005-03

7.  Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine.

Authors:  B Spivak; S Roitman; Y Vered; R Mester; E Graff; Y Talmon; N Guy; N Gonen; A Weizman
Journal:  Clin Neuropharmacol       Date:  1998 Jul-Aug       Impact factor: 1.592

Review 8.  Clozapine: balancing safety with superior antipsychotic efficacy.

Authors:  Herbert Y Meltzer
Journal:  Clin Schizophr Relat Psychoses       Date:  2012-10

9.  A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia.

Authors:  Herbert Y Meltzer; William V Bobo; Ajanta Roy; Karu Jayathilake; Yuejin Chen; Aygun Ertugrul; A Elif Anil Yağcioğlu; Joyce G Small
Journal:  J Clin Psychiatry       Date:  2008-02       Impact factor: 4.384

10.  Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia.

Authors:  Jari Tiihonen; Jaana T Suokas; Jaana M Suvisaari; Jari Haukka; Pasi Korhonen
Journal:  Arch Gen Psychiatry       Date:  2012-05
View more
  1 in total

1.  Methylation of the MAOA promoter is associated with schizophrenia.

Authors:  Hao Yang; Jiajue Li; Aicen Ji; Liping Hu; Xiufeng Zhang; Linlin Liu; Lili Qing; Ming Yan; Shengjie Nie
Journal:  Ann Transl Med       Date:  2020-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.